Just weeks after a stinging report was delivered to Aurobindo’s sterile drug plant in Telangana, the FDA has blasted a finished drug facility there.
An explosion at a pharmaceutical manufacturing facility has again claimed the lives of workers.
Eli Lilly and other multinational drugmakers will be audited in China. Plus, Takeda entered an R&D collab and disclosed a trial failure. And more.
Celgene returning tislelizumab rights after Bristol-Myers wraps its buyout would have "marginal" effect, BeiGene Chief Adviser Eric Hedrick said.
Big Pharma's older drugs face pricing pressure in China; Pfizer moves Upjohn HQ to Shanghai; Hansoh Pharma eyes $1 billion Hong Kong IPO.
Growth in China averaged 29% in Q1 among multinational pharmas Wolfe Pharma covers versus 8.2% in the U.S.
Two injected drugs manufactured by an Indian company with a history of sterility problems are being recalled because of contamination concerns.
GSK's Shingrix nabs Chinese nod; Roche's Chugai invests $1.15 billion in new R&D site; Japanese authority warns of Verzenio's side effect.
Rumor has it that several companies are in talks to buy Daiichi's over-the-counter drugs business, which could fetch $900 million.
Dendreon has signaled faith in its struggling prostate drug Provenge by signing a 10-year lease extension for its California manufacturing facility.